NCT06940895View on ClinicalTrials.gov

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

PHASE2RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

July 8, 2025

Study Completion Date

July 18, 2025

Conditions
Acanthosis Nigricans
Interventions
DRUG

Sirolimus 0.2%

sirolimus 0.2% gel

Trial Locations (1)

11209

RECRUITING

New York Harbor VA Brooklyn Campus, Brooklyn

Sponsors

Collaborators (1)

Nobelpharma
All Listed Sponsors
collaborator

Nobelpharma

INDUSTRY

lead

Narrows Institute for Biomedical Research

OTHER